ALK and non-small cell lung carcinoma: After the KN-024 trial, Health Canada approved pembrolizumab monotherapy in the first-line setting for a special cohort of advanced NSCLC patients with high PD-L1 expression (i.e., ≥50%), no epidermal growth factor receptor (EGFR), or anaplastic lymphoma kinase (ALK) aberration [4].